Investigational Injectable Cabotegravir Is Superior to Oral Standard of Care for Women
The study results showed that cabotegravir was 89% more effective than daily oral FTC/TDF for preexposure prophylaxis (PrEP).
An independent data safety monitoring board (DSMB) indicated that cabotegravir for HIV prevention in women met the primary objective of demonstrating superiority compared with the current standard of care for women: daily oral emtricitabine/tenofovir disoproxil fumarate 200-mg and 300-mg (FTC/TDF) tablets.
Further, the study results showed that cabotegravir was 89% more effective than daily oral FTC/TDF for preexposure prophylaxis (PrEP).
The early study unblinding for superior efficacy in this prevention trial in women follows results reported from a companion study, HPTN 083, that also established long-acting cabotegravir’s superiority to daily oral PrEP in preventing HIV among men who have sex with men and transgender women who have sex with men.
The HPTN 083 study includes 3223 participants in 20 sites across 7 countries in sub-Saharan Africa and is the first study of long-acting injectable therapy for HIV prevention among women.
The data showed that there was a statistically significant advantage for the women who received cabotegravir compared with the women who
received FTC/TDF.
Although both were highly effective at preventing HIV in the study population, cabotegravir was superior, according to a statement.
REFERENCE
ViiV Healthcare announces superiority of cabotegravir for PrEP in global HIV prevention in study in women. GCI Health [email]. Sent November 9, 2020.
Articles in this issue
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- Advise Patients About Self-Care Measures to Treat Mild to Moderate GI Issues
September 18th 2025
- Evaluation of Pharmacist-Driven Penicillin Allergy Reconciliation
September 17th 2025
- Pharmacists Can Apply Their Expertise to the Medical Psilocybin Act
September 16th 2025
- From Curiosity to Clinical Impact: Shremo Msdi’s Path in Pharmacy Research
September 15th 2025